Spots Global Cancer Trial Database for Cabozantinib and Nivolumab for Carcinoid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Cabozantinib and Nivolumab for Carcinoid Tumors

Official Title: Phase II Trial of Cabozantinib in Combination With Nivolumab for Advanced Carcinoid Tumors

Study ID: NCT04197310

Conditions

Carcinoid Tumor

Carcinoid Tumor of GI System

Neuroendocrine Tumors

Interventions

Nivolumab

Cabozantinib

Study Description

Brief Summary: This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. - Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.

Detailed Description: This is open-label, single-arm, phase II research study, studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus. * The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. * Cabozantinib will be administered orally, once daily * Nivolumab will be administered intravenously, every two weeks * The target enrollment for this study is 35 participants. * The U.S. Food and Drug Administration (FDA) has not approved cabozantinib or nivolumab for treating carcinoid tumors.